Revenue
2023
2024
2025
Crism Therapeutics Corporation (CRTX)
Price—Loading quote
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £231,000 | £25,000 | £45,000 | — |
| Research & development | £908,000 | £168,000 | £32,000 | — |
| Operating expenses | £2.0M | £901,000 | £183,000 | — |
| Operating income | −£1.9M | −£880,000 | −£170,000 | — |
| Operating margin | −812.99% | −3,520.00% | −377.78% | — |
| EBITDA | −£1.9M | −£566,000 | −£154,000 | — |
| EBITDA margin | −805.63% | −2,264.00% | −342.22% | — |
| Net income | −£1.9M | −£607,000 | −£196,000 | — |
| Net profit margin | −823.81% | −2,428.00% | −435.56% | — |
| Basic EPSper basic share | -£0.05 | -£0.02 | -£0.87 | -£0.29 |
| Diluted EPSper diluted share | -£0.05 | -£0.02 | -£0.87 | -£0.29 |
Owners
Reported major voting-rights holders
9.47%of voting rights
Premier Miton Group plcNotified Jun 16, 2026
View holders
| Holder | Voting rights |
|---|---|
Premier Miton Group plc | 9.47%Jun 16, 2026 · 7.5M votes |
Spreadex LTD | 2.53%Jul 28, 2026 · 2M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA National Storage Mechanism ↗Updated Sep 27, 2026
Community posts
CRISM reports higher development spending and a £1.41 million loss
CRISM Therapeutics ($CRTX) reported a first-half loss of £1.413 million, compared with £0.930 million a year earlier. Administrative expenses reached £1.52 million, including £956,000 of research and development spending. Operating cash out ...
